search
Back to results

Respiratory Function in Patients With Post-tuberculosis Lung Impairment

Primary Purpose

Lung Diseases, Obstructive, Pulmonary Rehabilitation, Lung TB

Status
Unknown status
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Pulmonary Rehabilitation
Sponsored by
Università degli Studi dell'Insubria
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Lung Diseases, Obstructive focused on measuring TB, Pulmonary rehabilitation, Lung function

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- Patients with post-TB lung impairment after completion of pulmonary tuberculosis treatment - Patients with post- TB impairment after spontaneous healing

Exclusion Criteria:

  • Any unstable medical condition
  • Musculoskeletal disorders contraindicating participation in the PR program
  • Cognitive impairment (Mini Mental State Examination <22)
  • Unable to sign informed consent

Sites / Locations

  • ICS Maugeri, IRCCSRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

pulmonary rehabilitation

Arm Description

Pulmonary rehabilitation program

Outcomes

Primary Outcome Measures

6-min walking test
Exercise capacity

Secondary Outcome Measures

dyspnoea
Modified BORG scale (0-10) 0 better, 10 worse
muscle fatigue
Modified Borg scale (0-10) 0 better, 10 worse
health related quality of life
st. George Respiratory Questionnaire 0 better, 100 worse
health status
COPD Assessment test-CAT (0-40) 0 better, 40 worse

Full Information

First Posted
January 14, 2019
Last Updated
January 28, 2019
Sponsor
Università degli Studi dell'Insubria
Collaborators
Fondazione Salvatore Maugeri, Azienda Ospedaliero Universitaria di Sassari, Instituto Nacional de Enfermedades Respiratorias
search

1. Study Identification

Unique Protocol Identification Number
NCT03821285
Brief Title
Respiratory Function in Patients With Post-tuberculosis Lung Impairment
Official Title
Evaluation of Respiratory Function in Patients With Post-tuberculosis Lung Impairment After Pulmonary Tuberculosis Treatment or After Spontaneous Healing
Study Type
Interventional

2. Study Status

Record Verification Date
January 2019
Overall Recruitment Status
Unknown status
Study Start Date
February 14, 2019 (Anticipated)
Primary Completion Date
July 31, 2020 (Anticipated)
Study Completion Date
January 14, 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Università degli Studi dell'Insubria
Collaborators
Fondazione Salvatore Maugeri, Azienda Ospedaliero Universitaria di Sassari, Instituto Nacional de Enfermedades Respiratorias

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Pulmonary tuberculosis (TB) is an important risk factor for chronic respiratory disease due to residual lung damage. A recent review of the literature on TB sequelae and rehabilitation has provided clear evidence that TB is definitively responsible for lung function impairment. Functional evaluation of TB patients after completion of pulmonary tuberculosis treatment or spontaneous healing should be considered as part of clinical care. Unfortunately, few studies are available in the literature investigating the physiopathology of lung damage, its impact on quality of life, the potential need for pulmonary rehabilitation (PR), and the effects of a PR program.Objectives of this prospective multicentre international study are: Primary Objective-to assess the exercise capacity 6-min walking test in patients with post-TB lung impairment after completion of pulmonary tuberculosis treatment or after spontaneous healing. Secondary Objectives-to assess the effects of the PR program on dyspnoea symptoms and muscle fatigue, quality of life.
Detailed Description
Methods Respiratory functional parameters at baseline and at the end of the 15 sessions rehabilitation programme (RP) will be collected at the participating Centre. Follow-up visit 1 year after completion of RP Baseline assessment After signature of the informed consent to the study, patients will undergo a Pre-screening Visit: data on medical history, current pharmacological therapies, smoking (pack/year), vaccinations, physical examination, vital parameters (blood pressure, heart rate, respiratory rate, oxygen saturation in arterial blood), co-morbidities and Mini Mental State Examination will be collected. Screening Visit (before the RP), during the visit the following data will be collected: number of TB disease episodes, detailed data on the last TB episode (age at onset of TB symptoms, age at TB diagnosis, anti-TB treatment duration, anti-TB drugs administered, socio-economic conditions, education level, physical examination, vital parameters, oxygen saturation in arterial blood, heart rate and respiratory rate). Pulmonary rehabilitation program tailored according to specific patient's needs. Baseline assessment of respiratory function: arterial blood gas (ABG) analysis, spirometry, diffusing capacity of the lungs for carbon monoxide (DLCO), overnight oximetry, electrocardiogram (ECG), chest X-ray (CXR), High-resolution computed tomography (HRCT) Assessment of the rehabilitation programme: functional evaluation (6MWT), muscle strength evaluation (five-repetition sit-to-stand test (5STS)), respiratory muscle strength (maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP)), symptoms evaluation (Dyspnea: Medical Research Council Questionnaire (MRC), Modified Borg pre/post 6MWT, Baseline and Transition Dyspnea Indexes (BDI-TDI) and Fatigue: Modified Borg pre/post 6MWT) Assessment of the Quality of Life (QoL): CAT and St George's Respiratory Questionnaire. Final assessment: A final assessment will be done at the end of the rehabilitation programme and will include: c) Only ABG, spirometry and DLCO d) and e). Pulmonary rehabilitation programme PR programme will include: At least 15 aerobic-training sessions by cycle ergometer supervised by a respiratory therapist (5 session per week, 30 minutes each: 5 minutes warm up, 20 minutes training and 5 minutes warm-down) at constant load (calculated with Hill equation, Hill K, et al. Estimating maximum work rate during incremental cycle ergometry testing from six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2008;89(9):1782-7.) with an adherence of at least 80%. At least 15 strength-training sessions for peripheral muscles (30 minutes calisthenics exercise) with an adherence of at least 80%. At least 3 face to face and/or group educational sessions, for: Optimization of inhalation techniques Exercise training and maintenance programs Daily physical activity Airways clearance techniques Long oxygen therapy home management. According to individual needs, the PR program should include: airways clearance techniques inspiratory muscles training (with Threshold®) Monitoring Anonymous data will be collected in a common electronic format (excel database). Adverse events (AEs) and severe adverse events (SAEs) will be reported and registered. Follow-up Follow-up visit 1 year after completion of RP will include: c) Only ABG, spirometry, DLCO and overnight oximetry d) and e) Statistical analysis A two-tailed p-value less than 0.05 will be considered statistically significant. Qualitative and quantitative variables will be described with absolute and relative (percentages) frequencies and means (standard deviations -SD) or medians (interquartile ranges -IQR) depending on their normality, respectively. The mean difference between the two study groups in the 6MWT will be evaluated using the Student's t-test. Differences in the variables associated to the secondary objectives will be evaluated using the Chi-square or Student's t-test for qualitative and quantitative variables. A two-tailed p-value less than 0.05 will be considered statistically significant.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Diseases, Obstructive, Pulmonary Rehabilitation, Lung TB
Keywords
TB, Pulmonary rehabilitation, Lung function

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Prospective, multicentre international
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
pulmonary rehabilitation
Arm Type
Experimental
Arm Description
Pulmonary rehabilitation program
Intervention Type
Procedure
Intervention Name(s)
Pulmonary Rehabilitation
Intervention Description
Pulmonary rehabilitation programme:15 aerobic-training sessions, 15 strength-training sessions for peripheral muscles, 3 face to face and/or Group educational sessions, if needed airways clearance techniques and/or inspiratory muscles training
Primary Outcome Measure Information:
Title
6-min walking test
Description
Exercise capacity
Time Frame
1 year
Secondary Outcome Measure Information:
Title
dyspnoea
Description
Modified BORG scale (0-10) 0 better, 10 worse
Time Frame
1 year
Title
muscle fatigue
Description
Modified Borg scale (0-10) 0 better, 10 worse
Time Frame
1 year
Title
health related quality of life
Description
st. George Respiratory Questionnaire 0 better, 100 worse
Time Frame
1 year
Title
health status
Description
COPD Assessment test-CAT (0-40) 0 better, 40 worse
Time Frame
1 year

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: - Patients with post-TB lung impairment after completion of pulmonary tuberculosis treatment - Patients with post- TB impairment after spontaneous healing Exclusion Criteria: Any unstable medical condition Musculoskeletal disorders contraindicating participation in the PR program Cognitive impairment (Mini Mental State Examination <22) Unable to sign informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dina Visca, Dr
Phone
+390331829111
Email
dina.visca@icsmaugeri.it
First Name & Middle Initial & Last Name or Official Title & Degree
Elisabetta Zampogna, Dr
Phone
+390331829503
Email
elisabetta.zampogna@icsmaugeri.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Giovan Battista Migliori, Prof
Organizational Affiliation
ICS Maugeri, IRCCS
Official's Role
Study Director
Facility Information:
Facility Name
ICS Maugeri, IRCCS
City
Tradate
State/Province
Varese
ZIP/Postal Code
21049
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dina Visca, Dr
Phone
+390331829111
Email
dina.visca@icsmaugeri.it
First Name & Middle Initial & Last Name & Degree
Elisabetta Zampogna, Dr
Phone
+390331829503
Email
elisabetta.zampogna@icsmaugeri.it

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
29487031
Citation
Tiberi S, Munoz-Torrico M, Duarte R, Dalcolmo M, D'Ambrosio L, Migliori GB. New drugs and perspectives for new anti-tuberculosis regimens. Pulmonology. 2018 Mar-Apr;24(2):86-98. doi: 10.1016/j.rppnen.2017.10.009. Epub 2018 Feb 24.
Results Reference
background
PubMed Identifier
27812638
Citation
Munoz-Torrico M, Rendon A, Centis R, D'Ambrosio L, Fuentes Z, Torres-Duque C, Mello F, Dalcolmo M, Perez-Padilla R, Spanevello A, Migliori GB. Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis? J Bras Pneumol. 2016 Sep-Oct;42(5):374-385. doi: 10.1590/S1806-37562016000000226.
Results Reference
result

Learn more about this trial

Respiratory Function in Patients With Post-tuberculosis Lung Impairment

We'll reach out to this number within 24 hrs